Loading...

bioMérieux S.A.

BIM.PAEURONEXT
Healthcare
Medical - Diagnostics & Research
92.80
1.35(1.48%)
U.S. Market opens in 5h 27m

bioMérieux S.A. (BIM.PA) Stock Competitors & Peer Comparison

See (BIM.PA) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Diagnostics & Research Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
BIM.PA€91.95+2.85%10.8B27.38€3.34+0.98%
ERF.PA€62.52+0.71%11.1B24.60€2.55+0.96%
LBIRD.PA€20.50+1.99%447M42.29€0.48N/A
MDXH.BR€3.02-3.76%85.6M-1.58-€1.91N/A
ALECR.PA€16,100.00+0.00%81.2M13.17€1,222.20N/A
BCART.BR€0.29+0.00%27.2M-0.32-€0.92N/A
ALBIO.PA€0.80+0.00%14.7M-0.20-€3.98N/A
ALPRE.PA€3.09+0.00%12.1M-2.92-€1.06N/A
EEP.MC€0.54N/A6.2M-54.00-€0.01N/A
MLAHC.PA€0.60+0.00%5.4M-10.00-€0.06N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

BIM.PA vs ERF.PA Comparison April 2026

BIM.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIM.PA stands at 10.8B. In comparison, ERF.PA has a market cap of 11.1B. Regarding current trading prices, BIM.PA is priced at €91.95, while ERF.PA trades at €62.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIM.PA currently has a P/E ratio of 27.38, whereas ERF.PA's P/E ratio is 24.60. In terms of profitability, BIM.PA's ROE is +0.10%, compared to ERF.PA's ROE of +0.12%. Regarding short-term risk, BIM.PA is less volatile compared to ERF.PA. This indicates potentially lower risk in terms of short-term price fluctuations for BIM.PA.Check ERF.PA's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions